Medically Reviewed | Last Updated: May 2026 | Based on peer-reviewed clinical trial data
| Key TakeawaysGLP-1 medications like semaglutide can produce 15 to 20% body weight reduction in clinical trials. Diet and exercise alone typically achieve around 5% over two years in structured programmes.GLP-1 drugs are designed to work alongside lifestyle changes, not instead of them. Every major pivotal trial delivered medication with structured diet and exercise counselling as a required component.Stopping medication without sustainable lifestyle habits is linked to significant weight regain. The STEP 1 trial found two-thirds of lost weight returns within one year of stopping semaglutide. |
Choosing between a GLP-1 medication and a traditional diet-and-exercise approach is not always straightforward. Here is what the clinical evidence actually says, and how to think about which path fits your health profile.
1. What Is a GLP-1 Medication, and How Does It Actually Work?
GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating.
GLP-1 receptor agonists (GLP-1 RAs) are medications that mimic this hormone, though they stay active in the body far longer than the natural version.
These medications work through three main mechanisms:
- Slow the rate at which your stomach empties food.
- Increase feelings of fullness (satiety).
- Suppress appetite signals in the brain.
The combined result is that you naturally eat less without feeling deprived.
Semaglutide is currently the most clinically studied GLP-1 medication for weight management.
It is available as a weekly injection and, more recently, as a daily oral tablet. The OASIS 4 trial, published in 2025, evaluated oral semaglutide at 25 mg daily for weight loss over 64 weeks, with FDA approval granted in December 2025.
Tirzepatide (Mounjaro) targets both GLP-1 and GIP receptors simultaneously, making it a dual agonist with outcomes comparable to or exceeding those of semaglutide.
In India, Novo Nordisk launched Wegovy (injectable semaglutide for weight management) in June 2025. Mounjaro (tirzepatide by Eli Lilly) was launched in India in March 2025.
Sun Pharma received DCGI approval in December 2025 for its generic semaglutide injection (brand name: Noveltreat), with semaglutide’s Indian patent expiring on March 20, 2026.
Over 10 generics companies have filed or are preparing regulatory submissions for their own versions.
2. What Can Diet and Exercise Realistically Achieve on Their Own?
The honest answer: meaningful, but modest for most people over the long term.
A 2021 review published in Frontiers of Endocrinology found that after two years, lifestyle interventions involving diet and exercise typically produce weight loss of approximately 5% of initial body weight. For someone weighing 90 kg, that translates to roughly 4.5 kg.
This is clinically significant. A 5 to 10% reduction in body weight is associated with meaningfully lower blood pressure, improved blood sugar control, reduced LDL cholesterol, and decreased risk of type 2 diabetes.
These benefits matter even if the number on the scale is modest.
The bigger challenge is sustainability. A systematic review published in PLOS ONE found that weight regain of approximately 55% of initial loss is common within one to two years after completing a structured diet-and-exercise programme. Long-term adherence is the central challenge.
There is also a biological factor. When the body loses weight, it adapts by lowering metabolic rate and increasing hunger hormones, a process known as metabolic adaptation.
This makes maintaining weight loss progressively harder over time, even with consistent effort.
Among exercise approaches, combined aerobic and resistance training produces the best outcomes. Physical activity guidelines recommend at least 150 minutes of moderate-intensity exercise per week for weight management, and up to 300 minutes for greater benefit.
3. What Do the Clinical Numbers Actually Say? A Direct Comparison
This is where the gap between the two approaches becomes clearly visible.
| Approach | Key Trial / Source | Mean Weight Loss | Duration |
|---|---|---|---|
| Semaglutide 2.4 mg (injection) | STEP 1 (NEJM, 2021) | ~14.9% body weight | 68 weeks |
| Semaglutide 7.2 mg (injection) | STEP UP Trial (2025) | ~20.7% body weight | ~72 weeks |
| Oral semaglutide 25 mg | OASIS 4 (2025) | ~13.6% body weight | 64 weeks |
| Tirzepatide (dual GLP-1/GIP) | SURMOUNT-1 (NEJM, 2022) | Up to 20.9% | 72 weeks |
| Semaglutide (cardiovascular pts) | SELECT Trial (Nat Med, 2024) | ~10.2% over 4 years | Up to 208 weeks |
| Diet + exercise (lifestyle only) | Meta-analysis (PubMed, 2021) | ~5% body weight | 2 years |
GLP-1 medications consistently outperform lifestyle interventions alone when measured on percentage weight reduction.
A meta-analysis of eight randomised controlled trials found that semaglutide produced a mean body weight reduction of 10.09% versus placebo, alongside a BMI reduction of 3.71 kg/m² and a waist circumference reduction of 8.28 cm.
One important caveat: almost all pivotal GLP-1 trials delivered medication alongside structured lifestyle counselling. The drugs were not tested as a standalone replacement for diet and exercise. This distinction is critical when interpreting the data.
4. Who Actually Qualifies for a GLP-1 Medication?
GLP-1 medications are not appropriate for everyone who wants to lose weight. Clinical guidelines and the DCGI approval framework in India define specific eligibility criteria.
You may be a candidate if:
- Your BMI is 30 kg/m² or higher (classified as obese), OR your BMI is 27 kg/m² or higher with at least one weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol.
- You have not achieved adequate results after a sustained, supervised effort with lifestyle changes alone.
- You are under the care of a qualified physician who can evaluate your full medical history, prescribe the appropriate dose, and supervise ongoing treatment.
- You do not have contraindications including a history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, active pancreatitis, or pregnancy.
For India specifically: the ICMR-INDIAB-17 national cross-sectional study (Anjana et al., Nature Medicine, 2023) documented 254 million adults with generalised obesity and 351 million with abdominal obesity in India.
According to NFHS-5 data, 1 in 4 Indians between ages 15 and 49 is now overweight or obese, with prevalence having nearly doubled over 15 years.
A note on BMI for Indian populations: Research and clinical consensus suggest that metabolic health risks associated with excess body fat may occur at lower BMI thresholds in South Asians compared to Western reference populations.
Evaluating abdominal obesity through waist circumference alongside BMI is strongly recommended. Always consult a specialist for a personalised clinical assessment.
5. What Side Effects and Safety Considerations Should You Know?
No medication is without trade-offs. GLP-1 medications have a well-characterised safety profile, but there are important factors to understand before starting treatment.
Most common side effects: Nausea, vomiting, diarrhoea, and stomach discomfort. These typically occur in the early weeks of treatment and tend to lessen over time as doses are gradually escalated.
In the STEP 1 trial, gastrointestinal events were the most frequently reported adverse events, though serious adverse events remained uncommon.
A 2025 long-term systematic review covering studies of 40 to 120 weeks confirmed generally acceptable safety profiles across multiple GLP-1 agents including semaglutide, liraglutide, tirzepatide, and exenatide.
Key contraindications: Personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, active pancreatitis, and pregnancy.
People with severe kidney or liver disease require careful clinical evaluation before starting treatment.
One concern specific to the Indian market: with generic semaglutide now available at lower price points, clinicians have raised concerns about self-medication.
A public interest litigation was filed in the Delhi High Court in early 2026 questioning GLP-1 approvals for obesity without large-scale India-specific clinical trials. These remain prescription drugs requiring medical supervision.
Self-medication is not appropriate or safe.
6. How Accessible Is GLP-1 Treatment in India Right Now?
The Indian GLP-1 landscape has shifted considerably since mid-2025.
Wegovy (injectable semaglutide for weight management) was launched in India by Novo Nordisk in June 2025. Mounjaro (tirzepatide by Eli Lilly) launched in March 2025 and became India’s top-selling medicine by value in October 2025. Sun Pharma received DCGI approval in December 2025 for its generic semaglutide injection (Noveltreat), with the Indian semaglutide patent expiring on March 20, 2026.
At least 10 generics companies had filed or were preparing regulatory submissions as of early 2026.
Rybelsus (oral semaglutide 14 mg, approved for type 2 diabetes) has been available in India and helped build familiarity with the GLP-1 class. Higher-dose oral formulations for weight management are in development and could further expand access once regulatory approvals are granted.
GLP-1 treatments are currently available through hospitals, specialty clinics, endocrinology practices, and retail pharmacies. Distribution is growing as the market expands and generic options enter.
7. Should You Combine Both Approaches? What the Evidence Suggests
This is the most clinically important point in this entire discussion.
All major pivotal trials, including STEP 1, STEP UP, and OASIS 4, delivered GLP-1 medication alongside structured lifestyle counselling. The drugs were tested as an adjunct to diet and exercise, not as a replacement for them.
The American Gastroenterological Association (AGA) Clinical Practice Guideline explicitly recommends pharmacotherapy in addition to lifestyle interventions for adults with obesity, with medication qualifying only after lifestyle changes alone produce inadequate results.
The combination also matters enormously for what happens if and when treatment stops.
The STEP 1 trial extension (Wilding et al., Diabetes, Obesity and Metabolism, 2022) found that within one year of stopping semaglutide, participants regained two-thirds of their prior weight loss. A 2025 meta-analysis in eClinicalMedicine confirmed that over 40% of lost weight may return within 28 weeks of stopping treatment in some patient populations.
The practical implication: the treatment window, when medication is most effective, is also the best opportunity to build durable lifestyle habits. GLP-1 medications are most likely to produce lasting outcomes when used to reinforce a long-term behavioural foundation, not to bypass it.
Bottom Line
GLP-1 medications represent a genuine clinical advance for people who meet the criteria for treatment. Clinical trials show 15 to 20% body weight reductions, compared to approximately 5% from diet and exercise over two years.
The SELECT trial (Nature Medicine, 2024) further demonstrated that weight reduction with semaglutide can be sustained for up to four years in appropriate patients with cardiovascular risk factors.
At the same time, GLP-1 medications are not a permanent substitute for healthy eating and regular physical activity.
The evidence is consistent: combining both approaches produces the best long-term outcomes, and stopping medication without sustainable habits in place is associated with significant weight gain.
If you think a GLP-1 medication may be appropriate for your health profile, speak with a qualified physician or endocrinologist. They can evaluate your BMI, comorbidities, and treatment goals before prescribing.
Frequently Asked Questions
Is a GLP-1 Medication More Effective Than Diet and Exercise Alone?
Based on current clinical trial data, yes. GLP-1 medications like semaglutide have demonstrated 14.9 to 20.7% body weight reductions in trials lasting 68 weeks or more, compared to approximately 5% from lifestyle interventions over two years. However, all major clinical trials delivered medication alongside lifestyle counselling, not in place of it. The combined approach consistently produces the most reliable and durable outcomes.
Can I Lose Weight on a GLP-1 Medication Without Changing My Diet?
GLP-1 medications may produce some weight loss without formal dietary changes, since they reduce appetite and slow gastric emptying. However, all pivotal trials including STEP 1 required structured lifestyle counselling as a protocol component. Evidence also shows that people who sustain lifestyle habits alongside medication maintain better weight outcomes when and if treatment is eventually stopped or reduced.
What Happens to My Weight Loss Results If I Stop a GLP-1 Medication?
The STEP 1 trial extension (Wilding et al., 2022) found that participants regained two-thirds of their lost weight within one year of stopping semaglutide. A 2025 meta-analysis in eClinicalMedicine found that over 40% of lost weight may return within 28 weeks of stopping treatment. These findings reinforce the clinical view that obesity is a chronic condition requiring ongoing management. Lifestyle habits built during treatment are a critical factor in longer-term weight maintenance after stopping medication.
| Medical DisclaimerThis article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 medications are prescription drugs in India and require evaluation and ongoing supervision by a qualified physician or endocrinologist. Do not start, stop, or alter any medication based on information read online. Always consult a licensed healthcare professional before making medical decisions. |
